Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2013; 19(8): 1219-1229
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1219
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1219
Table 5 Comparison of nonalcoholic fatty liver disease patients alive vs deceased n (%) (mean ± SD)
Variables | NAFLD patients alive (n = 263) | NAFLD patients deceased (n = 39) | P value |
At baseline | |||
Age (yr) | 45.2 ± 11.5 | 61.1 ± 13.8 | < 0.0001 |
Sex (% male) | 120 (45.6) | 12 (30.8) | 0.08 |
History of diabetes | 37 (14.1) | 11 (28.2) | 0.02 |
Systolic blood pressure (mmHg) | 134 ± 17 | 143 ± 21 | 0.02 |
Diastolic blood pressure (mmHg) | 83 ± 8 | 79 ± 10 | 0.03 |
Glucose (mg/dL) | 112 ± 38.6 | 132.7 ± 54.3 | 0.03 |
AST (U/L) | 42.2 ± 25.5 | 35.5 ± 20.0 | 0.06 |
ALT (U/L) | 64.2 ± 44.6 | 43.6 ± 27.4 | 0.000 |
AST/ALT ratio | 0.8 ± 0.4 | 1.0 ± 0.7 | 0.06 |
Albumin (g/dL) | 4.3 ± 0.3 | 4.0 ± 0.4 | < 0.0001 |
FRS | 7.9 ± 6.2 | 11.4 ± 5.2 | 0.000 |
Calculated CHD risk (%) | 15.3 ± 14.0 | 22.2 ± 17.1 | 0.02 |
NFS | -1.9 ± 1.3 | -0.8 ± 1.7 | 0.0004 |
NFS of intermediate or high probability of advanced liver fibrosis (%) | 94 (35.7) | 27 (69.2) | < 0.0001 |
Presence of histologically advanced liver fibrosis | 7/35 (20.0) | 5/11 (45.5) | 0.09 |
During the follow-up period | 77 (29.3) | 3 (7.7) | 0.004 |
Use of metformin | |||
Use of aspirin | 151 (57.4) | 16 (41.0) | 0.05 |
Use of simvastatin | 107 (40.7) | 3 (7.9) | < 0.0001 |
New events of coronary heart disease | 16 (6.1) | 14 (35.9) | < 0.0001 |
Liver complications | 1 (0.4) | 5 (12.8) | < 0.0001 |
At the end of follow-up | |||
BMI (kg/m2) | 33.9 ± 6.9 | 31.8 ± 8.2 | 0.1 |
Hematocrit (%) | 40.4 ± 4.1 | 34.5 ± 6.3 | < 0.0001 |
Glucose (mg/dL) | 122.0 ± 38.6 | 139.0 ± 62.3 | 0.12 |
AST/ALT ratio | 0.9 ± 0.5 | 1.3 ± 1.0 | 0.01 |
Albumin (g/dL) | 4.1 ± 0.3 | 3.3 ± 0.7 | < 0.0001 |
Creatinine (mg/dL) | 1.0 ± 0.5 | 1.7 ± 1.3 | 0.004 |
NFS | -0.9 ± 1.4 | 0.7 ± 2.3 | < 0.0001 |
NFS change per year (Median; IQR) | 0.07 (0.02, 0.12) | 0.14 (0.01, 0.31) | 0.03 |
NFS of intermediate to high probability of advanced liver fibrosis (%) | 168 (63.9) | 31 (79.5) | 0.05 |
- Citation: Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19(8): 1219-1229
- URL: https://www.wjgnet.com/1007-9327/full/v19/i8/1219.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i8.1219